Blitz Bureau
NEW DELHI: Amid serious concerns over recent introduction of multiple generic variants of weight loss drugs in the Indian market, the Centre on March 24 said it has intensified regulatory surveillance against the drug’s unauthorised sale and promotion. In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance, according to Health Ministry.
Concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.
“Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws,” said the government. The drugs controller, in collaboration with state regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorised sales and use.
“On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage,” according to a ministry statement. In the recent weeks, enforcement activities were significantly scaled up.
